anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During premarketing major depressive disorder studies, mania or hypomania occurred in 0.3% of venlafaxine hydrochloride extended-release capsules-treated patients and no placebo patients. In premarketing Social Anxiety Disorder studies, 0.2% venlafaxine hydrochloride extended-release capsules-treated patients and no placebo-treated patients experienced mania or hypomania. In premarketing panic disorder studies, 0.1% of venlafaxine hydrochloride extended-release capsules-treated patients and no placebo-treated patients experienced mania or hypomania. In all premarketing major depressive disorder trials with venlafaxine hydrochloride tablets, mania or hypomania occurred in 0.5% of venlafaxine-treated patients compared with no placebo patients. Mania/hypomania has also been reported in a small proportion of patients with mood disorders who were treated with other marketed drugs to treat major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, venlafaxine hydrochloride extended-release capsules should be used cautiously in patients with a history of mania.
The role of hepcidins, antimicrobial peptides involved in iron metabolism, immunity, and inflammation, is studied. First, gilthead seabream (Sparus aurata L.) head-kidney leucocytes (HKLs) were incubated with λ-carrageenin to study the expression of hepcidin and iron metabolism-related genes. While the expression of most of the genes studied was upregulated, the expression of ferroportin gene (slc40a) was downregulated. In the second part of the study, seabream specimens were injected intramuscularly with λ-carrageenin or buffer (control). The expression of the same genes was evaluated in the head kidney, liver, and skin at different time points after injection. The expression of Hamp1m, ferritin b, and ferroportin genes (hamp1, fthb, and slc40a) was upregulated in the head kidney of fish from the λ-carrageenin-injected group, while the expression of Hamp2C and Hamp2E genes (hamp2.3 and hamp2.7) was downregulated. In the liver, the expression of hamp1, ferritin a (ftha), slc40a, Hamp2J, and Hamp2D (hamp2.5/6) genes was downregulated in the λ-carrageenin-injected group. In the skin, the expression of hamp1 and (Hamp2A Hamp2C) hamp2.1/3/4 genes was upregulated in the λ-carrageenin-injected group. A bioinformatic analysis was performed to predict the presence of transcription factor binding sites in the promoter region of hepcidins. The primary sequence of hepcidin was conserved among the different mature peptides, although changes in specific amino acid residues were identified. These changes affected the charge, hydrophobicity, and probability of hepcidins being antimicrobial peptides. This study sheds light on the poorly understood roles of hepcidins in fish. The results provide insight into the regulatory mechanisms of inflammation in fish and could contribute to the development of new strategies for treat inflammation in farm animals.
The invention discloses 6-aryl substituted quinoline compounds and applications thereof, and belongs to the technical field of biomedicine. The invention discloses 6-aryl substituted quinoline and quinoline compounds and applications thereof. The novel compounds can be used as a PI3K[delta] inhibitor. Tests on PI3K[delta] kinase activity and PI3K[delta] kinase selective activity are carried out, and the test results show that the provided compounds have a prominent inhibiting effect on PI3K[delta] kinase activity and has a prominent selective effect on PI3K[delta] activity. Through testing the in-vitro cell proliferation of leukemia cell lines, people find that the disclosed compounds has different inhibiting effects on leukemia cells. The disclosed compounds, pharmaceutically-acceptable salts, deuterated substances, hydrates, solvates, chemically-protected prodrug, or compositions thereof can be used as the PI3K[delta] inhibitor, and can be used to treat and/or prevent inflammation or tumor.
The various embodiments herein disclose a composition in the form of an ointment for treating decubitus ulcers in diabetic and non diabetic patients. The composition comprises of therapeutic agents, zinc oxide, vegetable oils and powdered talc. The therapeutic agents include salts of nystatin, tetracycline and neomycin, respectively. The vegetable oils include an olive oil, a soya oil and a sweet almond oil. The composition is effective in treatment of bed sore ulcers or decubitus ulcers in, both diabetic and non-diabetic patients. A method is also provided for preparing a composition in the form of an ointment for treating decubitus ulcers.
Pneumonia is the most common serious infection in childhood. In the United States (US), pneumonia accounts for 1-4% of all emergency department (ED) visits in children (3-28 per 1,000 US children per year) and ranks among the top 3 reasons for pediatric hospitalization with \>100,000 hospitalizations per year (15-22 per 100,000 US children per year). Pneumonia also accounts for more days of antibiotic use in US children's hospitals than any other condition.

Emergency care for childhood pneumonia, including hospitalization rates, varies widely across the nation. A study examining hospital admission rates at 35 US children's hospitals from 2009-12 showed marked differences in severity-adjusted pneumonia hospital admission rates (median 31%; range 19-69%). Provider preferences and inaccurate risk perceptions contribute to these differences in hospitalization rates. Within the Intermountain Healthcare System in Utah, Dean et al. exposed large differences in admission rates (range 38-79%) among 18 individual ED providers providing care for \>2,000 adults with pneumonia. Differences were not explained by patient characteristics or illness severity and higher rates of hospitalization did not reduce hospital readmissions or mortality. In another multicenter study of 472 adults with pneumonia at \<4% risk of 30-day mortality estimated using objective severity scores, providers overestimated the risk of mortality in 5% of outpatients (range across institutions 0-12%) and 41% of inpatients (range across institutions 36-48%). These studies suggest that risk perceptions are often inaccurate, and potentially lead to unnecessary or prolonged hospitalizations and intensive therapies. Similar studies have not been performed in children because no valid prognostic tools exist to reliably predict pediatric pneumonia severity.
In clinical studies, 40% of PRIALT-treated patients had serum creatine kinase (CK) levels above the upper limit of normal (ULN), and 11% had CK levels that were greater than three times the ULN. In cases where CK was fractionated, only the muscle isoenzyme (MM) was elevated. The time to occurrence was sporadic, but the greatest incidence of CK elevation was during the first two months of treatment. One case of symptomatic myopathy with EMG findings, and two cases of acute renal failure associated with rhabdomyolysis and extreme CK elevations (17,000–27,000 IU/L) have been reported in PRIALT-treated patients. 

Therefore, monitor serum CK in patients undergoing treatment with PRIALT periodically (e.g., every other week for the first month and monthly as appropriate thereafter). Evaluate patients clinically and obtain CK measurements in the setting of new neuromuscular symptoms (e.g., myalgias, myasthenia, muscle cramps, asthenia) or a reduction in physical activity. If these symptoms continue and CK levels remain elevated or continue to rise, reduce the dose or discontinue the use of PRIALT.
Gradual, supervised withdrawal of ineralocorticoid receptor antagonists (spironolactone or eplerenone) and sodium glucose cotransporter 2 inhibitor (dapagliflozin or empagliflozin) over 4-16 weeks. Continued monitoring off study therapies during the cross-over phase.
The sympathetic nervous system is responsible for responding to stressful situations with involuntary actions, which will increase the neuronal activity in order to maintain body homeostasis. Stress is one of the most common causes of migraines. When it occurs for a prolonged period, there will be an over-stimulation of the sympathetic nervous system that will lead to dysautonomia, generating the rapid consumption of the neurotransmitter norepinephrine at the same time that adenosine, dopamine. It is believed that before the headache, the levels of norepinephrine are elevated, causing a vasoconstriction of extracranial vascularization, followed by a vasodilation resulting from the release of the other hormones previously mentioned, thus instituting the painful phase of migraine. Thus, migraine acts on the vascular system through changes in its homeostasis, predisposing the occurrence of future ischemic and/or hemorrhagic episodes to the brain and cardiac levels. The disruption of this system with the multifactorial mechanisms of migraine manifestation can then result in an increased risk of coronary heart disease and other changes in cardiac functioning, acquiring highly harmful potential for the human body. The interest in this study started in view of the numerous uncertainties within the scientific sphere regarding the possible systemic impacts caused by migraines after detailed research on the subject. The same becomes relevant, as it will contribute to the development of knowledge about headaches.
Background and objective: Prolonged standing is one of the significant contributors to chronic venous insufficiency (CVI) in industry workers. Yoga is proven to be an effective therapy in treating occupational hazards. The current study aimed to investigate the effect of yoga on CVI among industry workers. Methodology: Male workers (n = 100) from machinery manufacturing industries in Bangalore meeting the inclusion and exclusion criteria were recruited for the study. The yoga group received a specifically designed yoga module for 6 days a week for 12 weeks, and the control group was offered lifestyle suggestions. Plasma homocysteine was used as the primary outcome variable, whereas Venous Clinical Severity Score, ankle brachial pressure index (ABPI), ankle and calf circumference, CVI questionnaire, and Chalder fatigue scale were assessed as secondary variables at baseline and the end of 12 weeks of intervention. Results: Eighty-eight participants (yoga = 43, control = 45) completed the study. A one-way analysis of covariates (ANCOVA) was used to determine the significant differences between groups in the post-values. A significant difference was found between groups in plasma homocysteine (partial eta squared = 0.34, p < 0.001). All variables, except for ABPI, calf circumference, and ankle circumference, had shown statistically significant differences between the yoga and control groups after 12 weeks of intervention, with moderate to high effect sizes. There were no significant adverse events associated with the intervention. Conclusions: Yoga practices can reduce the symptoms of CVI along with vascular inflammation as indicated by reduced plasma homocysteine. Overall, yoga practices are found to be safe and efficacious for managing CVI. IEC Reference Number: RES/IEC-SVYASA/184/2021 Trial Registration Number (If Clinical Trial): CTRI/2021/02/030944.
COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
The invention discloses a three-oil one-lycopene soft capsule and a preparation method thereof. The soft capsule is formed by the content and a capsule wall material. The content comprises, by weight, 25-34 parts of perilla oil, 30-36 parts of pumpkin seed oil, 18-26 parts of garlic oil and 10-17 parts of lycopene. The capsule wall material comprises, by weight, 20-35 parts of gelatin, 5-8 parts of glycerinum and 15-35 parts of water. The raw materials used for the soft capsule are all green and healthy foods extracted from pure natural plant seeds and fresh fruits and have no toxic and side effects. The soft capsule has the effects of improving immunity, delaying senescence, preventing cancers, enhancing intelligence, protecting eyesight, resisting irritability, diminishing inflammation, killing bacteria, improving the sleep quality, regulating blood pressure, blood glucose and blood fat and preventing cardiovascular and cerebrovascular diseases; the formula is unique, and the soft capsule is especially suitable for middle-aged and elderly people and sub-health groups; the soft capsule technology is adopted, the dosage form is advanced, and it is guaranteed that the content of effective ingredients is high, the efficacy is lasting, active ingredients can be absorbed easily, the product is not prone to deterioration, and the soft capsule can be stored for 2-4 years at the normal temperature.
In this study, a proportion of subjects will receive study agent at its recommended dose and interval (45mg for subjects less than or equal to 100kg, or 90mg for subjects greater than 100kg; every 12 weeks after 2 starter doses at Weeks 0 and 4). The majority of subjects will have the opportunity to receive study agent less frequently during the randomization period depending on the subject's response. The study consists of a 4-week screening period; a 28-week open-label run-in period; a double-blind treatment period from Week 28 to Week 104; a 12 week post-treatment period; and a 20-week safety follow-up. Participants will be randomized for the double blind period into one of two study groups. Group 1 participants will receive an injection of the study medication at a 12 week dosing interval. Group 2 participants will undergo a placebo withdrawal and may receive study agents at an extended interval greater than 12 weeks. During the double-blind treatment period, subjects in Groups 1 and 2 will receive placebo as necessary to maintain the blind.
Overweight and obesity remain a major chronic health problem globally. The development of overweight and obesity is associated with various comorbidities including cardiovascular disease (CVD), dyslipidemia, hypertension, insulin resistance, certain cancers, and sleep apnea. Obesity is a strong modifiable risk factor for CVD, the leading cause of death worldwide. Dietary management is a cornerstone in the prevention, treatment, and control of overweight and obesity, CVD, and metabolic risk factors. Healthy dietary habits reduce the risk of several chronic lifestyle-related diseases as well as meet the demand for essential nutrients to the body to keep healthy.

Many dietary guidelines for the management of overweight and obesity in the general population recommended the reduction of body weight through calorie restriction, increase energy expenditure or followed both approaches. The most common method of weight loss has been daily, or continuous energy restriction (CER), which involves individuals restricting their energy restriction on daily basis by anywhere between 15-60%. Although CER is the most widely recommended calorie restriction approach for body weight loss and prevention of overweight and obesity, recent years have seen a surge in popularity of eating patterns including intermittent energy restriction (IER) as an alternative to CER due to its less restrictive nature and potential for higher rates of adherence. IER is an alternative weight loss method that may prove useful for individuals who find continued energy restriction difficult to maintain. Recent studies have shown IER to be comparable to CER in achieving weight loss in overweight and obese populations with the mean weight loss being 3-5 kg over 20 weeks. IER is considered to be effective for the management of obesity because IER requires the individual to focus on the energy-restricted for defined days during the week which is potentially more feasible than the standard approach of CER which is associated with poor compliance, and IER diet pattern have many beneficial metabolic effects achieved with weight loss and energy restriction when the person is no undergo negative energy balance.

Many peoples are worried about their increased body weight due to obesity-related adverse outcomes including coronary heart disease, type 2 diabetes, and metabolic disorder. There is a knowledge gap of evidence-based dietary patterns used for weight loss diet plan in the Nepalese context. The effectiveness IER using a 2-day severe energy-restricted strategy with 5 days of habitual eating pattern compared to CER has not been yet investigated within the Nepalese population. Therefore, the investigators intended to investigate the effectiveness of an IER diet using 2-day severe energy-restricted with 5 days of habitual eating pattern compared to a CER diet over six months.
Clinical efficacy was evaluated in 2 randomized, double-masked, placebo-controlled trials in which subjects with an anterior chamber cell grade greater than or equal to "2" (a cell count of 11 or higher) after cataract surgery were assigned to difluprednate ophthalmic emulsion or placebo (vehicle) following surgery. One drop of difluprednate ophthalmic emulsion or vehicle was self-instilled either 2 times per day or 4 times per day for 14 days, beginning the day after surgery. The presence of complete clearing (a cell count of 0) was assessed 3, 8 and 15 days post surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant benefit was seen in the 4 times per day difluprednate ophthalmic emulsion -treated group in ocular inflammation, at Days 8 and 15, and reduction of pain at Days 3, 8, and 15 when compared with placebo. The consolidated clinical trial results are provided below.

Figure 1 Percent of Subjects With Anterior Chamber Cells Clearing (Cell Count = 0)

Figure 2 Percent of Subjects Who Were Pain Free
This is a 2-way crossover (method used to switch patients from one treatment arm to another in a clinical study), randomized (the study medication is assigned by chance), placebo-controlled (an inactive substance that is compared with a study medication to test whether the medication has a real effect in a clinical study) study in 3 cohorts (group of individuals with similar characteristics) ie, 18 healthy young female participants; 18 healthy elderly female participants; 18 female patients with a past history of MDD. Participants will be randomized to 1 of 6 possible treatment groups: Group 1: Treatment AB, Group 2: Treatment BA, Group 3: Treatment AC, Group 4: Treatment CA, Group 5: Treatment AD, Group 6: Treatment DA, where Treatment A is placebo vaccination, Treatment B is typhoid vaccination, Treatment C is psychosocial stress (Trier Social Stress Test \[TSST\]) followed by placebo vaccination, and Treatment D is psychosocial stress (TSST) followed by typhoid vaccination. Participants from each of the 3 cohorts will be randomized to these 6 treatment groups. In all the 6 groups the 1st treatment comes under Period 1 and 2nd treatment under Period 2 (eg, In Group 1: Treatment A \[Period 1\] and Treatment B \[Period 2\]) and there will be a minimally 7- and maximally 14- day washout period (period when no treatment is received) between the study periods. The study will consist of an eligibility screening examination (from 21 to 2 days prior to Day 1 of Period 1); a run-in visit (only prior to Period 1) in which eligible participants will be briefly explained about the cognitive test battery and immediately thereafter the baseline of cognitive function will be measured via these tests; 2 single-blind (a clinical study in which the person giving the treatment, but not the patient, knows which treatment the patient is receiving) treatment periods (2-way crossover); and a follow-up examination by phone (approximately 7 to 14 days after last treatment \[Period 2\]). For each participant, the maximal study duration will not exceed 8 weeks.
Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
The present invention relates to novel prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate cancer antigens", and the use of such prostate cancer antigens for detecting disorders of the prostate, particularly the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer associated nucleic acid molecules are provided encoding novel prostate cancer associated polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention.  The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
The invention relates to a constipation removal Chinese herbal preparation and a preparation and using method of the constipation removal Chinese herbal preparation. The constipation removal Chinese herbal preparation is used for treating constipation, colitis, prostatitis, prostatic hyperplasia and hemorrhoid swelling. The constipation removal Chinese herbal preparation comprises oral liquid, clysis liquid and absorbent cotton plasters. According to the constipation removal Chinese herbal preparation and the preparation and using method, comprehensive and overall treatment on difficult miscellaneous diseases can be accurately carried out; the viscera balance and the index deviation can be adjusted in a large-scale manner; and a series of etiological factors which cause the diseases are removed. The constipation removal Chinese herbal preparation is absorbed by the mucosa and has the beneficial effects of being rapid in absorbing speed and effect taking speed. Meanwhile, through different medicinal material combinations in the formula, the focuses such as the viscera foundation balance, the benign prostatic hyperplasia and the hernia can be treated or eliminated. In addition, according to the constipation removal Chinese herbal preparation, the medicine preparation technology is simple; the formula and the taking explanations are simple; packages are small; and the constipation removal Chinese herbal preparation is easy to carry.